Home › Funds › Fairmount Funds Management LLC › VRDN
Fairmount Funds Management LLC position in VRDN
VIRIDIAN THERAPEUTICS INC · Health Care
Fairmount Funds Management LLC reported holding 5,090,928 shares of VRDN (VIRIDIAN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$104.8M, representing 6.57% of its reported portfolio and ranking #6 among its reported holdings. Fairmount Funds Management LLC has disclosed VRDN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Fairmount Funds Management LLC's VRDN position evolved
Fairmount Funds Management LLC first disclosed a stake in VRDN in Q3 2023 at 1,369,623 shares (US$21.0M). The position peaked in Q4 2025 at 3,914,458 shares, worth US$121.8M. Across 13 filings, Fairmount Funds Management LLC increased the stake 4 time(s), trimmed it 0 time(s) and left it unchanged 8 time(s). The most recent filing (Q3 2026) shows 5,090,928 shares valued at US$104.8M. Notable position changes include a 35% increase in Q1 2024 (shares fell 26% over the following quarter), a 87% increase in Q3 2024 (shares fell 16% over the following quarter), a 30% increase in Q2 2026 (shares rose 12% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.37M | $21.01M | New |
| Q4 2023 | 1.37M | $29.83M | Hold |
| Q1 2024 | 1.85M | $32.32M | Add |
| Q2 2024 | 1.85M | $24.01M | Hold |
| Q3 2024 | 3.45M | $78.39M | Add |
| Q4 2024 | 3.45M | $66.06M | Hold |
| Q1 2025 | 3.45M | $46.45M | Hold |
| Q2 2025 | 3.46M | $48.37M | Hold |
| Q3 2025 | 3.46M | $74.66M | Hold |
| Q4 2025 | 3.91M | $121.82M | Add |
| Q1 2026 | 3.91M | $76.57M | Hold |
| Q2 2026 | 5.09M | $93.52M | Add |
| Q3 2026 | 5.09M | $104.82M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About VRDN and 13F data
VRDN (VIRIDIAN THERAPEUTICS INC) is a Health Care company. 40 other funds we track also report a position in VRDN — the largest reported positions include Paradigm Biocapital Advisors LP (US$227.1M), Bellevue Group AG (US$146.4M), Kynam Capital Management, LP (US$126.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding VRDN
- Paradigm Biocapital Advisors LP 12.41M sh · $227.08M · Q3 2026
- Bellevue Group AG 7.11M sh · $146.38M · Q3 2026
- Kynam Capital Management, LP 6.15M sh · $126.59M · Q3 2026
- RTW INVESTMENTS, LP 4.98M sh · $102.03M · Q3 2026
- RA CAPITAL MANAGEMENT, L.P. 5.96M sh · $81.79M · Q3 2026
- Novo Holdings A/S 4.87M sh · $78.92M · Q3 2026
- Venrock Adviser, LLC 3.26M sh · $67.08M · Q3 2026
- Deep Track Capital, LP 3.83M sh · $64.34M · Q3 2026
- Atlas Venture Life Science Advisors, LLC 4.50M sh · $61.83M · Q3 2026
- Caligan Partners LP 3.08M sh · $57.34M · Q3 2026
- Context Capital Management, LLC 49.00M sh · $56.47M · Q3 2026
- Avoro Capital Advisors LLC 2.50M sh · $51.48M · Q3 2026
More on Fairmount Funds Management LLC
FAQ
How long has Fairmount Funds Management LLC held VRDN?
Fairmount Funds Management LLC has disclosed VRDN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Fairmount Funds Management LLC's current position in VRDN?
As of Q3 2026, Fairmount Funds Management LLC holds 5.09M shares of VRDN (VIRIDIAN THERAPEUTICS INC), valued at $104.82M, representing 6.57% of its reported portfolio and ranking #6.
Has Fairmount Funds Management LLC been buying or selling VRDN?
In the latest 13F filing (Q3 2026), Fairmount Funds Management LLC held unchanged its position in VRDN. The position peaked in Q4 2025 at 3.91M shares.
Which other funds hold VRDN?
Other major institutional holders of VRDN include Paradigm Biocapital Advisors LP, Bellevue Group AG, Kynam Capital Management, LP, among 40 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.